Cargando…

Effects of tolcapone and bromocriptine on cognitive stability and flexibility

RATIONALE: The prefrontal cortex (PFC) and basal ganglia (BG) have been associated with cognitive stability and cognitive flexibility, respectively. We hypothesized that increasing PFC dopamine tone by administering tolcapone (a catechol-O-methyltransferase (COMT) inhibitor) to human subjects should...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cameron, Ian G. M., Wallace, Deanna L., Al-Zughoul, Ahmad, Kayser, Andrew S., D’Esposito, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869902/ https://www.ncbi.nlm.nih.gov/pubmed/29427081 http://dx.doi.org/10.1007/s00213-018-4845-4

Ejemplares similares

The Dopamine Agonist Bromocriptine Differentially Affects Fronto-Striatal Functional Connectivity During Working Memory
por: Wallace, Deanna L., et al.
Publicado: (2011)

Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers
por: Kayser, Andrew S., et al.
Publicado: (2016)

Utility of tolcapone in fluctuating Parkinson’s disease
por: Stocchi, Fabrizio, et al.
Publicado: (2006)

Formulation of Sustained Release Hydrophilic Matrix Tablets of Tolcapone with the Application of Sedem Diagram: Influence of Tolcapone’s Particle Size on Sustained Release
por: Nardi-Ricart, Anna, et al.
Publicado: (2020)

The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease
por: Zhang, Pei-Lan, et al.
Publicado: (2018)

Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
por: Artusi, Carlo Alberto, et al.
Publicado: (2021)

Micro- and Nano-Systems Developed for Tolcapone in Parkinson’s Disease
por: Casanova, Yaquelyn, et al.
Publicado: (2022)

Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors
por: Bhakta, Savita G, et al.
Publicado: (2017)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease
por: Truong, Daniel D
Publicado: (2009)

Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
por: Sant'Anna, Ricardo, et al.
Publicado: (2016)

Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
por: Maser, Tyler, et al.
Publicado: (2017)

Addition of Tolcapone in Intrajejunal Levodopa Infusion Therapy Requires a Pronounced Dose Reduction
por: Schröter, Nils, et al.
Publicado: (2020)

Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses
por: Qiu, Mengjie, et al.
Publicado: (2020)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Catechol-o-methyltransferase inhibitor tolcapone improves learning and memory in naïve but not in haloperidol challenged rats
por: Mihaylova, Anita, et al.
Publicado: (2019)

Tolcapone in Obsessive Compulsive disorder: A Randomized Double-Blind Placebo-Controlled Crossover Trial
por: Grant, Jon E., et al.
Publicado: (2021)

Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
por: Sant’Anna, Ricardo, et al.
Publicado: (2023)

An Approach for Identifying Brainstem Dopaminergic Pathways Using Resting State Functional MRI
por: Vytlacil, Jason, et al.
Publicado: (2014)

Striatal dopamine synthesis and cognitive flexibility differ between hormonal contraceptive users and nonusers
por: Taylor, Caitlin M, et al.
Publicado: (2023)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Management of pituitary tumour apoplexy with bromocriptine in pregnancy
por: Janssen, Nina M, et al.
Publicado: (2012)

Bromocriptine Does Not Alter Speed–Accuracy Tradeoff
por: Winkel, Jasper, et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Repositioning of bromocriptine for treatment of acute myeloid leukemia
por: Lara-Castillo, María Carmen, et al.
Publicado: (2016)

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases
por: Simon, Rebecca, et al.
Publicado: (2018)

Temporal resolution of idiopathic granulomatous mastitis with resumption of bromocriptine therapy for prolactinoma
por: Bouton, Marcia E., et al.
Publicado: (2015)

The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails
por: ul- Abideen, Zain, et al.
Publicado: (2021)

AB086. The effect of Xuanju compound capsule combined with bromocriptine
por: Bian, Jun, et al.
Publicado: (2016)

Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone
por: Schacht, Joseph P., et al.
Publicado: (2022)

Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy
por: Chopra, Sandeep, et al.
Publicado: (2012)

Dopaminergic Challenge With Bromocriptine in Patients With Severe Brain Injury
por: Celik, JB, et al.
Publicado: (2015)

Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients
por: Khalilzade, Saied Hossein, et al.
Publicado: (2015)

Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis
por: Tang, Yiqun, et al.
Publicado: (2023)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
por: Antonini, Angelo, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_hai0posuofsueh5al9hna95e8l